Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cyclopharm's Enterprise Value is A$64.15 Mil.
Cyclopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-17.81 Mil. Therefore, Cyclopharm's EV-to-EBIT ratio for today is -3.60.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cyclopharm's Enterprise Value is A$64.15 Mil.
Cyclopharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-16.04 Mil. Therefore, Cyclopharm's EV-to-EBITDA ratio for today is -4.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cyclopharm's Enterprise Value is A$64.15 Mil.
Cyclopharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was A$16.69 Mil. Therefore, Cyclopharm's EV-to-Revenue ratio for today is 3.84.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Cyclopharm's Enterprise Value is A$64.15 Mil.
Cyclopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-19.44 Mil. Therefore, Cyclopharm's EV-to-FCF ratio for today is -3.30.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Cyclopharm (ASX:CYC) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Cyclopharm's current Enterprise Value is A$64.15 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-17.81 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Cyclopharm's current Enterprise Value is A$64.15 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-16.04 Mil.
Cyclopharm's current Enterprise Value is A$64.15 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was A$16.69 Mil.
Cyclopharm's current Enterprise Value is A$64.15 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-17.33 Mil.
Cyclopharm's current Enterprise Value is A$64.15 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-19.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm Enterprise Value Related Terms
Cyclopharm Enterprise Value Historical Data
* Premium members only.
The historical data trend for Cyclopharm's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CYC vs MCK, COR, CAH: Enterprise Value Comparison
For the Medical Distribution subindustry, Cyclopharm's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm Enterprise Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Cyclopharm's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Cyclopharm's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a Enterprise Value of A$64.15 Mil as of Jun. 28, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Cyclopharm and its competitors.
Is Cyclopharm's Enterprise Value too high?
Cyclopharm's current Enterprise Value is A$64.15 Mil. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Enterprise Value compare to MCK and COR?
Cyclopharm's Enterprise Value of A$64.15 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Distribution company?
A good Enterprise Value depends on the Medical Distribution industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Cyclopharm and its competitors. Cyclopharm's current Enterprise Value is A$64.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current Enterprise Value is A$64.15 Mil. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Enterprise Value is A$64.15 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
Enterprise Value: A$64.15 Mil
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
46GF Score
Get the complete analysis for ASX:CYC
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
